GAITHERSBURG, Md. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23 rd Annual Global Investment Conference , being held
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September Approximately $218 Million in Cash and Short-Term Investments to Advance Obesity and Liver Disease Pipeline GAITHERSBURG, Md. , Aug. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc.
GAITHERSBURG, Md. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021 . Altimmune management will host a conference call for
AdCOVID was well tolerated but did not stimulate an adequate immune response in healthy volunteers Altimmune will discontinue further development of AdCOVID and focus its resources on its ongoing obesity and liver programs Altimmune also provides an update on its T-COVID™ Phase 1/2 Clinical Trial
Weight loss of 5.4% achieved at 6 weeks of treatment with 1.8 mg once weekly dose, surpassing the 2% pre-established treatment target Ascending multi-dose regimen well-tolerated without necessity for dose titration Trial continuing with 12-week data expected in Q3 2021 Company plans to file an
GAITHERSBURG, Md. , May 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the 2021 Jefferies Virtual Healthcare Conference , being held June 1 - 4, 2021 .
Similar Neutralization Titers Observed for Both Ancestral and B.1.351 South African Variant Phase I Clinical Trial of AdCOVID Expected to Report Data in June 2021 GAITHERSBURG, Md. , May 26, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today
Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline GAITHERSBURG, Md. , May 17, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company,
GAITHERSBURG, Md. , May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021 . Altimmune management will host a conference call for investors
Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2 Sterilizing Immunity Believed to be Critical for Blocking Viral Transmission Phase I Clinical Trial of AdCOVID Expected to Report Data in June 2021 GAITHERSBURG, Md.
